Chronic hepatitis B infection has a high risk concerning morbidity and mortality. Cirrhosis and hepatocellular carcinoma are the most important complications. Interferon alpha reduces these complications and mortality. In this paper, we aimed to evaluate epidemiological characteristics and response to six-month interferon alpha treatment (5 MU/m2, three times a week by subcutaneous injections) in children with chronic hepatitis B infection. A retrospective analysis of 28 cases admitted to our department were performed. Children tolerated the therapy well. Response to therapy was found in 32% of cases. Nonresponders had a histologically low hepatic activity index, low serum transaminase levels and high levels of hepatitis B virus DNA. We suggest that these patients must be treated with a higher dosage or that treatment must be of longer.

Keywords: kronik hepatit B enfeksiyonu, interferon-alfa, chronic hepatitis B, interferon alpha